Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ) has provided an update.
Hansoh Pharmaceutical has granted 4,992,330 restricted share units under its post-IPO RSU scheme to 804 grantees, including one executive director and 803 employees, at a grant price of HK$7.8592 per share against a market price of HK$37.30. The awards, which will vest in three tranches over three years starting April 29, 2026, are tied to company performance indicators, individual evaluations and clawback provisions covering compliance, safety, quality and underperformance, reinforcing long-term incentives and alignment between staff and shareholders.
The only director grantee, executive director Dr. Lyu Aifeng, received RSUs linked solely to existing shares held or to be held by the RSU trustee, meaning no new shares will be issued for his awards and no shareholder approval is required under Hong Kong listing rules. By broadening equity-based remuneration across its workforce without providing financial assistance for participation, the company is signaling an emphasis on retention, performance discipline and governance standards while containing dilution risk for investors.
The most recent analyst rating on (HK:3692) stock is a Buy with a HK$47.00 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.
More about Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited is a Hong Kong-listed biopharmaceutical company focused on research, development, manufacturing and commercialization of innovative and generic medicines. The group primarily serves the China healthcare market, targeting major therapeutic areas and relying on a large base of professional employees to support its growth and operations.
Average Trading Volume: 9,534,243
Technical Sentiment Signal: Buy
Current Market Cap: HK$238.7B
Find detailed analytics on 3692 stock on TipRanks’ Stock Analysis page.